VYNE Therapeutics reports Q1 EPS (15c) vs. ($1.74) last year

Reports Q1 revenue $0.1M vs. $0.1M last year. “During the first quarter, we made steady progress in advancing our VYN201 program toward a Phase 2b trial,” said David Domzalski, President and CEO of VYNE. “We are rapidly activating clinical trial sites and expect to dose the first subject in the trial this quarter. In addition, we recently received IND clearance for our VYN202 program to proceed and expect to dose the first healthy volunteers in our Phase 1a trial this quarter. We look forward to updating our stakeholders on our progress in the coming months.”